Abstract:Purpose: To compare prospectively the effects of radiofrequency (RF) ablation after transcatheter arterial chemoembolization (TACE) with those of RF ablation alone in the treatment of recurrent hepatocellular carcinoma (HCC). Materials and Methods: This study was approved by the institutional ethics committee, and all patients gave written informed consent. From January 2002 to December 2006, 139 patients with recurrent HCC measuring 5 cm in diameter or smaller were randomized to receive either sequential TACE and RF ablation (sequential treatment group, n = 69) or RF ablation alone (RF ablation group, n = 70). The survival curves were constructed with the Kaplan-Meier method and compared by using the log-rank test. Bonferroni correction was applied when multiple comparisons were performed. P < .0083 (.05 divided by 6) was considered indicative of a statistically significant difference. Results: The 1-, 3-, and 5-year overall survival rates were 94%, 69%, and 46%, respectively, for the sequential treatment group and 82%, 47%, and 36% for the RF ablation group (P = .037). The corresponding recurrence-free survival rates were 80%, 45%, and 40% for the sequential treatment group and 64%, 18%, and 18% for the ablation group (P = .005). At subgroup analyses, the overall survival for the sequential treatment group was better than that for the RF ablation group for patients with tumor recurrence 1 year or less after initial treatment (P = .004) and those with tumors measuring 3.1-5.0 cm (P = .002) but not for those with tumor recurrence more than 1 year after initial treatment (P = .421) and those with tumors 3.0 cm or smaller (P = .478). The recurrence-free survival in the sequential treatment group was better than that in the RF ablation group for patients with tumors measuring 3.1-5.0 cm (P < .001) but not for those with tumors 3.0 cm or smaller (P = .204). For recurrence-free survival, there was no significant difference between the two groups for patients with tumor recurrence 1 year or less or more than 1 year after initial treatment (P = .020 and P = .111, respectively). Logistic regression analysis showed that treatment allocation and the interval between initial treatment and tumor recurrence were significant prognostic factors for overall survival, whereas the interval between initial treatment and tumor recurrence, treatment allocation, and tumor size were significant prognostic factors for recurrence-free survival. Conclusion: The efficacy of sequential TACE-RF ablation is better than that of RF ablation alone for recurrent HCC. (C)RSNA, 2011

Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment.

Surgical Resection Plus Radiofrequency Ablation for the Treatment of Multifocal Hepatocellular Carcinoma.

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients

Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis

Comparison of the Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Versus Monotherapy in Patients with Liver Cancer

Radiofrequency Ablation, TACE and Combined Treatment for Multiple Recurrent HCC Patients Within the Milan Criteria

Efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation in advanced hepatocellular carcinoma patients

Effectiveness of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Effect of RFA combined with TACE for treatment of early hepatocellular carcinoma with liver cirrhosis

Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis.

The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma

RFA and TACE for Treatment of Hepatocellular Carcinoma

Combined Hepatectomy and Radiofrequency Ablation Versus TACE in Improving Survival of Patients with Unresectable BCLC Stage B HCC.

Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis

Combination Therapy with PD-1 Blockade and Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma：a Retrospective Study

Radiofrequency Ablation with or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: a Prospective Randomized Trial.

Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial.

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis

Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study

A system evaluation of radiofrequency ablation plus transcatheter hepatic arterial chemoembolization for primary hepatocellular carcinoma